- Home
- JBLU vs TARS Comparison
JBLU vs TARS Comparison
Compare JBLU & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- TARS
- Stock Information
- Founded
- JBLU 1998
- TARS 2016
- Country
- JBLU United States
- TARS United States
- Employees
- JBLU N/A
- TARS N/A
- Industry
- JBLU Air Freight/Delivery Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- JBLU Consumer Discretionary
- TARS Health Care
- Exchange
- JBLU Nasdaq
- TARS Nasdaq
- Market Cap
- JBLU 2.1B
- TARS 2.1B
- IPO Year
- JBLU N/A
- TARS 2020
- Fundamental
- Price
- JBLU $6.10
- TARS $53.07
- Analyst Decision
- JBLU Sell
- TARS Strong Buy
- Analyst Count
- JBLU 13
- TARS 5
- Target Price
- JBLU $6.55
- TARS $56.00
- AVG Volume (30 Days)
- JBLU 22.9M
- TARS 735.9K
- Earning Date
- JBLU 01-28-2025
- TARS 02-25-2025
- Dividend Yield
- JBLU N/A
- TARS N/A
- EPS Growth
- JBLU N/A
- TARS N/A
- EPS
- JBLU N/A
- TARS N/A
- Revenue
- JBLU $9,279,000,000.00
- TARS $129,621,000.00
- Revenue This Year
- JBLU N/A
- TARS $917.88
- Revenue Next Year
- JBLU $5.07
- TARS $78.70
- P/E Ratio
- JBLU N/A
- TARS N/A
- Revenue Growth
- JBLU N/A
- TARS 801.96
- 52 Week Low
- JBLU $4.50
- TARS $20.08
- 52 Week High
- JBLU $8.31
- TARS $57.14
- Technical
- Relative Strength Index (RSI)
- JBLU 31.99
- TARS 58.11
- Support Level
- JBLU $7.66
- TARS $45.72
- Resistance Level
- JBLU $8.21
- TARS $54.08
- Average True Range (ATR)
- JBLU 0.45
- TARS 2.80
- MACD
- JBLU -0.20
- TARS 0.24
- Stochastic Oscillator
- JBLU 14.01
- TARS 76.66
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.